Recurrent and Metastatic Head and Neck Cancers
Publication Date: December 15, 2022
Key Points
Key Points
- Head and neck cancers frequently arise from the oral cavity, oropharynx, larynx, hypopharynx, or nasopharynx, and more rarely from salivary glands or paranasal sinuses.
- Immune-checkpoint inhibitors (ICIs) are now approved as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), with or without chemotherapy.
- The guideline provides recommendations regarding immunotherapy and biomarker testing for this diverse and complex group of diseases.
Treatment
...Treatme...
...ecommendation 1.1Programmed death-ligand 1 (...
...commendation 1.2PD-L1 combined positive score (CP...
...tion 1.3Tumor mutational burden (TMB) testing ma...
...mmendation 1.4TMB ≥10 should be int...
....1Pembrolizumab monotherapy or pembrolizumab, pla...
...mmendation 2.2Pembrolizumab, platinum, and...
...endation 3.1Pembrolizumab or nivolumab should be...
...ommendation 4.1Toripalimab, camrelizumab or t...
Recommendation 4.2Programmed cell death protein 1...
...ommendation 5.1For patients with oligometastatic H...
...dation 6.1Pembrolizumab may be offere...
...on 6.2Pembrolizumab may be offered to patients...
...arkers and Recommendations by PD-L1 St...
...2. Recommendations by Sub...